Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥ 18 and \< 65 years~* Good general condition (according to history and clinical examination)~* Written informed consent~* No pregnancy~* No breast feeding~* Efficacious contraception (e.g. oral, double-barrier) during the study and 4 weeks after termination of the study~* No participation in other clinical trials 4 weeks before, during participation, and 4 weeks after participation in this study~* Planned travel period between 6 and 28 days~* Planned travel to South- and Southeast Asia~* Planned time to arrival in South- or Southeast Asia ≤ 24 hours~Exclusion Criteria:~* Pregnancy~* Breast feeding~* Age \< 18 and ≥ 65 years~* No written informed consent~* Chronic gastrointestinal disease and/ or immune insufficiency~* Low general condition (according to history and clinical examination)~* Regular medication with gastrointestinal side-effects and/or immunosuppressive medication~* Participation in other clinical trials 4 weeks before, during and 4 weeks after termination of the study~* No efficacious contraception~* Planned travel period \< 6 and \> 28 days~* Planned travel outside South- and Southeast Asia~* Vaccination against cholera using DUKORAL within 12 months prior to inclusion~* Planned time to arrival in South- or Southeast Asia \> 24 hours~* Known hypersensitivity against rifaximin or rifamycin-derivatives in general~* Known lactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): None
- Lactose (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).